Prevalence of Hirsutism Among Reproductive-Aged African American Women
Overview
Affiliations
Hirsutism is the most common clinical symptom of hyperandrogenism, but racial and ethnic-specific thresholds have not been established. Our objective was to characterize hirsutism using self-report of hair growth in a large sample of African American women. The Study of Environment, Lifestyle, and Fibroids is a prospective community-based cohort study of African American women (23-34 at recruitment). A total of 1568 participants received the modified Ferriman-Gallwey (mFG) pictorial assessment and were asked if they were ever bothered by excess hair. We estimated the prevalence of hirsutism (mFG score ≥8) and associations of acne, polycystic ovary syndrome (PCOS), and menstrual cycle characteristics with hirsutism. We also explored hirsutism defined by the 95th percentile of scores in our cohort (mFG = 11) and a newly recommended criterion, mFG = 4. We could determine hirsutism status in 1556 women. Thirty-seven percent reported being bothered by excess hair, and 10% met the mFG criterion for hirsutism. History of severe facial acne was positively associated with hirsutism (prevalence ratio: 1.90; 95% confidence interval [CI]: 1.30-2.76), as was physician-diagnosed PCOS (2.22, 95% CI: 1.30-3.81). Women with irregular menstrual cycles were also more likely to report hirsutism (1.78, 95% CI: 1.00-3.18). Results were similar using mFG ≥11 and attenuated using mFG ≥4. Hirsutism prevalence was 10% in this community sample of African American women and was associated with PCOS, severe acne, and irregular menstrual cycles suggesting this represented hirsutism caused by hyperandrogenism. Ethnically diverse, population-based studies assessing the association between mFG score and androgen levels are needed to better understand the hirsutism threshold as a clinical marker of hyperandrogenism.
Oliveira T, Oliveira T, Santana D, Rocha A, Candido A, Comim F Arch Endocrinol Metab. 2024; 68:e230271.
PMID: 39420908 PMC: 11213573. DOI: 10.20945/2359-4292-2023-0271.
Thomsen K, Jalaboi R, Winther O, Lomholt H, Lorentzen H, Hogsberg T Lasers Surg Med. 2024; 57(1):80-87.
PMID: 39308029 PMC: 11776445. DOI: 10.1002/lsm.23843.
Alkhezi F, AlNemash N, AlMutairi J, Saleh S, Almutairi M, Saleh S Womens Health Rep (New Rochelle). 2024; 5(1):579-587.
PMID: 39206018 PMC: 11347869. DOI: 10.1089/whr.2023.0176.
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Xiong T, Fraison E, Kolibianaki E, Costello M, Venetis C, Kostova E Cochrane Database Syst Rev. 2023; 7:CD008565.
PMID: 37462232 PMC: 10353291. DOI: 10.1002/14651858.CD008565.pub3.
Oliveira T, Oliveira T, Rocha A, Reis F, Candido A, Premaor M Arch Dermatol Res. 2022; 315(6):1783-1787.
PMID: 36508021 DOI: 10.1007/s00403-022-02495-0.